EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

Gabriela Rodríguez-Macías, Oscar Briz iD, Candela Cives-Losada iD, María C Chillón iD, Carolina Martínez-Laperche, Ibon Martínez-Arranz, Ismael Buño iD, Marcos González-Díaz, José L Díez-Martín, Jose J G Marin iD, Rocio I R Macias iD

Cancers · 11.06.2023 · 15 (12) · 3145

DOI: 10.3390/cancers15123145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 11.06.2023. Verfasst von Gabriela Rodríguez-Macías und 10 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, 37007 Sala…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Junta de Castilla y León, Fundación Mutua Madrileña, Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite its often low efficacy and high toxicity, the standard treatment for acute myeloid leukemia (AML) is induction chemotherapy with cytarabine and idarubicin. Here, we have investigated the role of transporters and drug-metabolizing enzymes in this poor outcome. The expression levels (RT-qPCR) of potentially responsible genes in blasts collected at diagnosis were related to the subsequent response to two-cycle induction chemotherapy. The high expression of uptake carriers (ENT2), export ATP-binding cassette (ABC) pumps (MDR1), and enzymes (DCK, 5-NT, and CDA) in the blasts was associated with a lower response. Moreover, the sensitivity to cytarabine in AML cell lines was associated with ENT2 expression, whereas the expression of ABC pumps and enzymes was reduced. No ability of any AML cell line to export idarubicin through the ABC pumps, MDR1 and MRP, was found. The exposure of AML cells to cytarabine or idarubicin upregulated the detoxifying enzymes (5-NT and DCK). In AML patients, 5-NT and DCK expression was associated with the lack of response to induction chemotherapy (high sensitivity and specificity). In conclusion, in the blasts of AML patients, the reduction of the intracellular concentration of the active metabolite of cytarabine, mainly due to the increased expression of inactivating enzymes, can determine the response to induction chemotherapy.

Schlagwörter

Stichwörter der Autor:innen

AMLblood cancerchemoresistancechemotherapyprognosis

Autor:innen und Institutionen

  • Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.
  • Department of Hematology, Gregorio Marañón General University Hospital, 28007 Madrid, Spain.
  • Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, 28029 Madrid, Spain.
  • Hematology, Biomedical Research Institute of Salamanca, Salamanca University Hospital, 37007 Salamanca, Spain.
  • CIBER in Oncology (CIBER-ONC), Carlos III National Institute of Health, 28029 Madrid, Spain.
  • Gregorio Marañón Health Research Institute (IiSGM), 28007 Madrid, Spain.

ORCID-Profile: Oscar Briz, Candela Cives-Losada, María C Chillón, Ismael Buño, Jose J G Marin, Rocio I R Macias

Förderung

  • Junta de Castilla y León
  • Fundación Mutua Madrileña
  • Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III
  • Ministry of Science, Innovation, and Universitie

Zitieren

APA

Rodríguez-Macías, G., Briz, O., Cives-Losada, C., Chillón, M. C., Martínez-Laperche, C., Martínez-Arranz, I., Buño, I., González-Díaz, M., Díez-Martín, J. L., Marin, J. J. G., & Macias, R. I. R. (2023). Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy. Cancers, 15(12), 3145. https://doi.org/10.3390/cancers15123145

Vancouver

Rodríguez-Macías G, Briz O, Cives-Losada C, Chillón MC, Martínez-Laperche C, Martínez-Arranz I, et al. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy. Cancers. 2023;15(12):3145. doi:10.3390/cancers15123145

BibTeX
@article{RodrguezMacas2023,
  author = {Rodríguez-Macías, Gabriela and Briz, Oscar and Cives-Losada, Candela and Chillón, María C and Martínez-Laperche, Carolina and Martínez-Arranz, Ibon and Buño, Ismael and González-Díaz, Marcos and Díez-Martín, José L and Marin, Jose J G and Macias, Rocio I R},
  title = {Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {12},
  pages = {3145},
  doi = {10.3390/cancers15123145}
}
Kostenlos starten →